
A new Oxera report has found that the NHS benefits by up to £571 million annually in bowel cancer care alone thanks to biomedical scientists, active in 95% of patient pathways The Institute of Biomedical Science (IBMS) is announcing the findings of an independent report showing that the presence of biomedical scientists in the bowel cancer patient pathway benefits the NHS by an estimated £115 million to £571 million per year. This amount is equivalent to the annual salaries of between 1,700 and 8,500 specialist doctors or between 3,400 and 17,000 nurses annually. The report, commissioned from Oxera, highlights the
Biomedical Scientists Benefit NHS Up to £571M in Bowel Cancer Care as seen on The Hippocratic Post.